MEDITE CANCER DIAGNOSTICS, INC. (OTCMKTS:MDIT) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
On January 2, 2018, the Board of Directors (the “Board”) of MEDITE Cancer Diagnostics, Inc. (the “Company”) held a meeting whereby the Board accepted the resignation of Susan Weisman, the Chief Financial officer of the Company, effective January 5. The Company has entered into a Consulting Agreement with Ms. Weisman to assist the Company during a transition period. Thereafter the Board elected Stephen Von Rump, the Company’s Chief Executive Officer, to serve as interim Chief Financial Officer until a permanent replacement is found.
On January 2, 2018, the Board accepted the resignation of Eric Goehausen from the position of Director of the Company. Thereafter the Board appointed Gregory Fortunoff to the position of Director of the Company to serve until his resignation or removal.
Gregory Fortunoff, Age 48, Director
Gregory Fortunoff is an experienced manufacturing and financial executive with over 25 year experience of healthcare investing experience. Since 2014 through the present, Mr. Fortunoff has been the owner of Jeftex Corporation and is responsible for overseeing the operations of this 87 year old textile converter company. From 2009 until 2014, Mr. Fortunoff was the owner of G-2 Trading, LLC before selling the company in 2014. Mr. Fortunoff managed the daily operations of this equity trading firm with $100,000,000 in positions. From 2006 to 2011, Mr. Fortunoff served as a Board Member of American Medical Alert, Inc., a small cap medical device and communication company which was ultimately sold at a premium to a private company. In 1992, Mr. Fortunoff earned a B.A. degree in Marketing from Syracuse University. Mr. Fortunoff is not currently, nor has he been an officer or director of any company required to file reports with the Securities Exchange Commission.
Item 9.01
Financial Statements and Exhibits
|
Exhibit No. |
Description |
|
Resignation Letter of Susan Weisman |
|
|
99.2 |
Resignation Letter of Eric Goehausen |
Medite Cancer Diagnostics, Inc. Exhibit…To view the full exhibit click here
About MEDITE CANCER DIAGNOSTICS, INC. (OTCMKTS:MDIT)
MEDITE Cancer Diagnostics, Inc. (MEDITE), formerly CytoCore, Inc., is a medical technology company engaged in the development, engineering, manufacturing and marketing of molecular biomarkers and medical devices and consumables for detection, risk assessment and diagnosis of cancer, precancerous conditions and related diseases. The Company develops, manufactures and sells a range of laboratory devices and consumable supplies for its target market in the histology and cytology cancer diagnostics segment. The Company offers a range of histology laboratory devices for processing tissue, from receiving the tissue in the laboratory to the final diagnosis. The Company offers USE33, an ultrasonic decalcification instrument that runs the process under controlled temperatures. The Company also offers TPC15 Duo or Trio, TES99, TES Valida, M530, A550, M380, TST44 and COT20 linear staining systems. In addition, the Company also offers RCM9000, ACS720 and TWISTER glass and robotic coverslippers.
